Financial
FY2025 revenue $4.34bn (-0.7%); operating margin 18.6%; net income $850.0m.
Cash $1.63bn; debt $1.99bn.
Illumina
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Strong
Customer rating
No reviews yet
Financial health
Band: StrongListed: ILMN
FY2025 revenue $4.34bn (-0.7%); operating margin 18.6%; net income $850.0m.
Cash $1.63bn; debt $1.99bn.
Source: official results release · Year ended 2025-12-28 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | US$4.3bn | -0.7% | US$807m | US$850m | Illumina |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Feb 2025: China's commerce ministry added Illumina to its Unreliable Entity List; Illumina said it was in talks with the authorities. Jan 2026: Fierce reported Illumina was still working through its China export troubles.
Cyber & information governance
Jul 2025: Illumina agreed to pay $9.8m to settle a US False Claims Act whistleblower case alleging it sold genomic sequencing systems to federal agencies without adequate product cybersecurity (2016-2023); Illumina denied the allegations and liability. NHS DSPT status not yet checked.
Regulatory & clinical safety
No product recalls, FDA/MHRA safety notices or warning letters involving Illumina found in HSH's search of the last 24 months.
Contract performance
Jun 2025: Genomics England extended Illumina's 2019 whole genome sequencing contract for the NHS Genomic Medicine Service to Mar 2027 (with a buyer break option after Jul 2026), adding £4.67m to cover extra lab and staff costs.
Competitors
No competitors linked yet.